We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00655109
First Posted: April 9, 2008
Last Update Posted: April 9, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Greiner, Jack V., OD DO PhD
  Purpose
To compare the clinical efficacy of olopatadine and fluticasone in a 3-week single center, double-masked, randomized, placebo controlled parallel treatment conjunctival allergen challenge (CAC) study in patients with allergic conjunctivitis

Condition Intervention Phase
Conjunctivitis, Allergic Drug: Olopatadine Drug: Fluticasone Drug: Saline Drug: Artificial tears Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis

Resource links provided by NLM:


Further study details as provided by Greiner, Jack V., OD DO PhD:

Primary Outcome Measures:
  • Ocular itching [ Time Frame: Minutes following CAC ]

Secondary Outcome Measures:
  • Ocular redness [ Time Frame: Minutes following CAC ]

Enrollment: 60
Study Start Date: February 2008
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Olopatadine
Drug: Olopatadine
Ophthalmic solution
Active Comparator: 2
Fluticasone
Drug: Fluticasone
Nasal spray
Placebo Comparator: 3
Placebo nasal spray
Drug: Saline
Nasal spray
Placebo Comparator: 4
Placebo Eyedrops
Drug: Artificial tears
Ophthalmic Solution

Detailed Description:
Study will evaluate the efficacy of nasal anti-allergic therapy compared to ocular anti-allergic therapy in the prevention of ocular allergic symptoms.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age & either sex, any race
  • Willing and able to follow all instructions and attend all study visits
  • Positive history of ocular allergies
  • Reproducible positive ocular allergic reaction induced by conjunctival allergen challenge

Exclusion Criteria:

  • Have planned surgery during trial period
  • Female currently pregnant, planning a pregnancy, or lactating
  • Use of disallowed medications
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00655109


Locations
United States, Massachusetts
Ophthalmic Research Associates, Inc
North Andover, Massachusetts, United States, 01845
Sponsors and Collaborators
Greiner, Jack V., OD DO PhD
Investigators
Principal Investigator: Jack V Greiner, OD, DO, PhD ORA, Inc.
  More Information

Responsible Party: Jack V. Greiner, OD DO PhD, Ophthalmic Research Associates
ClinicalTrials.gov Identifier: NCT00655109     History of Changes
Other Study ID Numbers: 08-003-04
First Submitted: April 2, 2008
First Posted: April 9, 2008
Last Update Posted: April 9, 2008
Last Verified: April 2008

Keywords provided by Greiner, Jack V., OD DO PhD:
Allergic conjunctivitis
Allergic rhinoconjunctivitis

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Olopatadine Hydrochloride
Ophthalmic Solutions
Lubricant Eye Drops
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Pharmaceutical Solutions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Antirheumatic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents